Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Amneal Pharmaceuticals ( (AMRX) ).
On February 2, 2026, Amneal Pharmaceuticals’ subsidiary, Amneal Pharmaceuticals LLC, and certain of its subsidiaries entered into a second amendment to their November 14, 2023 term loan credit agreement, refinancing and partially converting existing term loans into approximately $2.09 billion of new Amendment No. 2 Term Loans while keeping the August 1, 2032 maturity date unchanged. The repricing lowered the interest rate margins on the amended term loans by 50 basis points—to 2.00% over the base rate and 3.00% over the secured overnight financing rate—and introduced the ability to reprice the debt after August 2, 2026 without a prepayment premium, changes the company estimates will reduce its annual cash interest expense by about $11 million, strengthening its capital structure and lowering ongoing financing costs for stakeholders.
The most recent analyst rating on (AMRX) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
AMRX scores highest on technical strength (price above major moving averages with positive MACD) and a supportive earnings narrative (raised guidance and strong Q3 growth). The score is held back primarily by weak underlying profitability (very low net margin/ROE and declining free cash flow growth) and a very unfavorable headline valuation (extremely high P/E).
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals is a specialty and generic drug manufacturer focused on developing, manufacturing and distributing pharmaceutical products, primarily in the United States, with an emphasis on cost-effective therapies across multiple therapeutic areas.
Average Trading Volume: 2,456,266
Technical Sentiment Signal: Buy
Current Market Cap: $4.3B
Learn more about AMRX stock on TipRanks’ Stock Analysis page.